The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Novartis’ efforts to strengthen its wide ... Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and Fabhalta should fuel growth. NVS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

have recommended reimbursement of Fabhalta in the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor 5,6 Novartis Pharmaceuticals Canada ...

have recommended reimbursement of Fabhalta in the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor 5,6 Novartis Pharmaceuticals Canada Inc.